Literature DB >> 20506301

Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268.

John R Zysk1, Dan Widzowski, Linda A Sygowski, Katharine S Knappenberger, Nathan Spear, Charles S Elmore, Peter Dorff, Hongyan Liu, James Doherty, Vijay Chhajlani.   

Abstract

We previously reported the absence of high-affinity binding of the group II metabotropic glutamate receptor agonists LY 354,740 and LY 379,268 to the D2L dopamine receptor. A rebuttal to our findings has since been reported (see Introduction section); this study represents our response. Analysis by LCMS of LY 354,740 and LY 379,268 used in this study revealed the correct molecular mass for these compounds. Both LY 354,740 and LY 379,268 exhibited potent agonist activity for mGluR₂ in the ³⁵S-GTPγS assay. Functionally, neither compound displayed antagonist activity in the GTPγS assay with recombinant D₂. At concentrations up to 10 μM, both compounds failed to displace [³H]-raclopride, [³H]-PHNO, or [³H]-domperidone in filter-binding assays under isotonic (120 mM NaCl or N-methyl glucamine) or low-ionic strength (no NaCl or N-methyl glucamine) conditions. Some displacement of [³H]-domperidone (20-40%) was observed at 30 μM of LY 354,740 under low-ionic strength and under isotonic conditions in the absence of NaCl. No displacement of [³H]-domperidone was detected in a two site model at lower (<100 nM) concentrations of either compound. Moreover, no D₂ activity was observed for LY 354,740 or LY 379,268 in the CellKey™ (cellular dielectric spectroscopy) assay. In this communication, we discuss the possible reasons for differences in our study and the previously published work and implications of these studies for mechanisms of antipsychotic action.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20506301     DOI: 10.1002/syn.20817

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012).

Authors:  Philip Seeman
Journal:  Psychopharmacology (Berl)       Date:  2012-03-13       Impact factor: 4.530

2.  Activation of group II metabotropic glutamate receptors inhibits the discriminative stimulus effects of alcohol via selective activity within the amygdala.

Authors:  Reginald Cannady; Julie J M Grondin; Kristen R Fisher; Clyde W Hodge; Joyce Besheer
Journal:  Neuropsychopharmacology       Date:  2011-07-06       Impact factor: 7.853

3.  Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells.

Authors:  Kazue Hisaoka-Nakashima; Kanako Miyano; Chie Matsumoto; Naoto Kajitani; Hiromi Abe; Mami Okada-Tsuchioka; Akinobu Yokoyama; Yasuhito Uezono; Norimitsu Morioka; Yoshihiro Nakata; Minoru Takebayashi
Journal:  J Biol Chem       Date:  2015-04-13       Impact factor: 5.157

4.  Methamphetamine and core temperature in the rat: ambient temperature, dose, and the effect of a D2 receptor blocker.

Authors:  Karen E Sabol; Danielle M Yancey; H Anton Speaker; Scott L Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2013-06-04       Impact factor: 4.530

Review 5.  Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.

Authors:  Carolina Muguruza; J Javier Meana; Luis F Callado
Journal:  Front Pharmacol       Date:  2016-05-20       Impact factor: 5.810

6.  mGluR2/3 mechanisms in primate dorsolateral prefrontal cortex: evidence for both presynaptic and postsynaptic actions.

Authors:  L E Jin; M Wang; S-T Yang; Y Yang; V C Galvin; T C Lightbourne; D Ottenheimer; Q Zhong; J Stein; A Raja; C D Paspalas; A F T Arnsten
Journal:  Mol Psychiatry       Date:  2016-08-09       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.